Browsing Category
Pharma Industry News
4745 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Biomea Fusion posts 15% weight loss in primate model as BMF-650 nears IND for oral GLP-1 therapy
Biomea Fusion’s BMF-650 shows 15% weight loss in primates. Find out why investors are watching its IND filing and Phase I trial timeline for obesity treatment.
Waters introduces touch-authenticated HPLC system for end-to-end lab traceability
Waters Corporation launches Alliance iS HPLC Software 2.0 to improve audit readiness, data traceability, and touchscreen security in global pharma labs.
AtomVie Global Radiopharma partnering with TerraPower Isotopes to secure actinium-225 for global cancer therapy development
AtomVie Global Radiopharma signs agreement with TerraPower Isotopes to secure actinium-225 supply, aiming to advance CDMO-based cancer radiotherapies.
CERo Therapeutics gets FDA boost for CER-1236, eyes breakthrough in AML cell therapy
CERo Therapeutics secures FDA orphan drug status for CER-1236 in AML, advancing its novel CER-T immunotherapy platform. Read what this means for investors.
Can Lilly’s flat $499/month Zepbound pricing reshape obesity drug access in the U.S.?
Lilly expands Zepbound access via LillyDirect, offering all FDA-approved doses for $499/month. Explore the implications for patients and the GLP-1 drug market.
CSL wins FDA approval for ANDEMBRY, the first monthly anti-factor XIIa therapy for hereditary angioedema
CSL’s ANDEMBRY gains U.S. FDA approval as the first monthly HAE treatment targeting factor XIIa. Learn how it redefines disease control for patients.
Lupin signs China licensing deal for COPD drug Tiotropium DPI with Sino Universal Pharmaceuticals
Lupin enters China’s COPD market with a Tiotropium DPI licensing deal. Learn how this move shapes its global respiratory growth strategy.
Gene therapy ElenaVet achieves 90% success rate in canine osteoarthritis trial
CureLab Veterinary’s ElenaVet™ gene therapy shows 90% success in easing osteoarthritis pain in dogs, with rapid relief and no major side effects.
Blueprint Medicines highlights long-term clinical and real-world data for Ayvakit at EHA and EAACI 2025
Blueprint Medicines presents strong long-term survival and safety data for Ayvakit in systemic mastocytosis at EHA and EAACI 2025. Explore the clinical and market impact.
Enliven Therapeutics’ ELVN-001 shows strong Phase 1 results in CML, with Phase 3 plans in 2026
ELVN-001 from Enliven Therapeutics shows 47% MMR in CML trial; see what this means for the stock outlook and future Phase 3 plans. Read more.